Report Detail
Global (United States, European Union and China) Heart Failure Drugs Market Research Report 2019-2025
- RnM3604015 |
- 19 July, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.
The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China, and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher heart failure cases in the region.
One of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period.
In 2019, the market size of Heart Failure Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Heart Failure Drugs.
This report studies the global market size of Heart Failure Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Heart Failure Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Amgen
AstraZeneca
Bayer
Novartis
Gilead
GlaxoSmithKline
Pfizer
Teva Pharmaceutical industries
Market Segment by Product Type
Beta Blockers
ARBs
ACE Inhibitors
Market Segment by Application
Hospital
Pharmacy
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Heart Failure Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Heart Failure Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Heart Failure Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Heart Failure Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Beta Blockers
- 1.3.3 ARBs
- 1.3.4 ACE Inhibitors
- 1.4 Market Segment by Application
- 1.4.1 Global Heart Failure Drugs Market Share by Application (2019-2025)
- 1.4.2 Hospital
- 1.4.3 Pharmacy
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Heart Failure Drugs Market Size
- 2.1.1 Global Heart Failure Drugs Revenue 2014-2025
- 2.1.2 Global Heart Failure Drugs Sales 2014-2025
- 2.2 Heart Failure Drugs Growth Rate by Regions
- 2.2.1 Global Heart Failure Drugs Sales by Regions 2014-2019
- 2.2.2 Global Heart Failure Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Heart Failure Drugs Sales by Manufacturers
- 3.1.1 Heart Failure Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Heart Failure Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Heart Failure Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Heart Failure Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Heart Failure Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Heart Failure Drugs Price by Manufacturers
- 3.4 Key Manufacturers Heart Failure Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Heart Failure Drugs Market
- 3.6 Key Manufacturers Heart Failure Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Beta Blockers Sales and Revenue (2014-2019)
- 4.1.2 ARBs Sales and Revenue (2014-2019)
- 4.1.3 ACE Inhibitors Sales and Revenue (2014-2019)
- 4.2 Global Heart Failure Drugs Sales Market Share by Type
- 4.3 Global Heart Failure Drugs Revenue Market Share by Type
- 4.4 Heart Failure Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Heart Failure Drugs Sales by Application
6 United States
- 6.1 United States Heart Failure Drugs Breakdown Data by Company
- 6.2 United States Heart Failure Drugs Breakdown Data by Type
- 6.3 United States Heart Failure Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Heart Failure Drugs Breakdown Data by Company
- 7.2 European Union Heart Failure Drugs Breakdown Data by Type
- 7.3 European Union Heart Failure Drugs Breakdown Data by Application
8 China
- 8.1 China Heart Failure Drugs Breakdown Data by Company
- 8.2 China Heart Failure Drugs Breakdown Data by Type
- 8.3 China Heart Failure Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Heart Failure Drugs Breakdown Data by Company
- 9.2 Rest of World Heart Failure Drugs Breakdown Data by Type
- 9.3 Rest of World Heart Failure Drugs Breakdown Data by Application
- 9.4 Rest of World Heart Failure Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Heart Failure Drugs Sales by Countries
- 9.4.2 Rest of World Heart Failure Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Amgen
- 10.1.1 Amgen Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.1.4 Heart Failure Drugs Product Introduction
- 10.1.5 Amgen Recent Development
- 10.2 AstraZeneca
- 10.2.1 AstraZeneca Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.2.4 Heart Failure Drugs Product Introduction
- 10.2.5 AstraZeneca Recent Development
- 10.3 Bayer
- 10.3.1 Bayer Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.3.4 Heart Failure Drugs Product Introduction
- 10.3.5 Bayer Recent Development
- 10.4 Novartis
- 10.4.1 Novartis Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.4.4 Heart Failure Drugs Product Introduction
- 10.4.5 Novartis Recent Development
- 10.5 Gilead
- 10.5.1 Gilead Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.5.4 Heart Failure Drugs Product Introduction
- 10.5.5 Gilead Recent Development
- 10.6 GlaxoSmithKline
- 10.6.1 GlaxoSmithKline Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.6.4 Heart Failure Drugs Product Introduction
- 10.6.5 GlaxoSmithKline Recent Development
- 10.7 Pfizer
- 10.7.1 Pfizer Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.7.4 Heart Failure Drugs Product Introduction
- 10.7.5 Pfizer Recent Development
- 10.8 Teva Pharmaceutical industries
- 10.8.1 Teva Pharmaceutical industries Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Heart Failure Drugs
- 10.8.4 Heart Failure Drugs Product Introduction
- 10.8.5 Teva Pharmaceutical industries Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Heart Failure Drugs Sales Channels
- 11.2.2 Heart Failure Drugs Distributors
- 11.3 Heart Failure Drugs Customers
12 Market Forecast
- 12.1 Global Heart Failure Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Heart Failure Drugs Sales Forecast by Type
- 12.3 Global Heart Failure Drugs Sales Forecast by Application
- 12.4 Heart Failure Drugs Forecast by Regions
- 12.4.1 Global Heart Failure Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Heart Failure Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Heart Failure Drugs. Industry analysis & Market Report on Heart Failure Drugs is a syndicated market report, published as Global (United States, European Union and China) Heart Failure Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Heart Failure Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
